ONCOLOGY Vol 35, Issue 5 | Oncology

Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma

May 15, 2021

Clinical Quandaries

Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.

Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature

May 13, 2021

Review Article

Focal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates

May 13, 2021

Review Article

This review article published in the journal ONCOLOGY® looks at the successful clinical development of immunotherapies, PARP inhibitors, and antibody-drug conjugates for the management of metastatic triple-negative breast cancer and how these have improved the survival outcome of patients. Over the coming years, therapeutic developments in precision medicine will likely change the treatment landscape and might make the current definition of triple-negative breast cancer as a disease that is estrogen receptor, progesterone receptor, and HER2 negative obsolete.